300 related articles for article (PubMed ID: 7660512)
1. Reversion of human prostate tumorigenic growth by azatyrosine.
Benoit RM; Eiseman J; Jacobs SC; Kyprianou N
Urology; 1995 Sep; 46(3):370-7. PubMed ID: 7660512
[TBL] [Abstract][Full Text] [Related]
2. Isolation of azatyrosine-induced revertants from ras-transformed human mammary epithelial cells.
Kyprianou N; Taylor-Papadimitriou J
Oncogene; 1992 Jan; 7(1):57-63. PubMed ID: 1741165
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
4. Transfected neu oncogene induces human prostate cancer metastasis.
Zhau HY; Zhou J; Symmans WF; Chen BQ; Chang SM; Sikes RA; Chung LW
Prostate; 1996 Feb; 28(2):73-83. PubMed ID: 8604395
[TBL] [Abstract][Full Text] [Related]
5. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorigenicity.
Gao AC; Lou W; Isaacs JT
Cancer Res; 1998 Apr; 58(7):1391-4. PubMed ID: 9537237
[TBL] [Abstract][Full Text] [Related]
9. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
10. Azatyrosine inhibits neurite outgrowth of PC12 cells induced by oncogenic Ras.
Fujita-Yoshigaki J; Yokoyama S; Shindo-Okada N; Nishimura S
Oncogene; 1992 Oct; 7(10):2019-24. PubMed ID: 1328988
[TBL] [Abstract][Full Text] [Related]
11. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene.
Sikes RA; Chung LW
Cancer Res; 1992 Jun; 52(11):3174-81. PubMed ID: 1350510
[TBL] [Abstract][Full Text] [Related]
13. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G; Hauser CA
Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
[TBL] [Abstract][Full Text] [Related]
14. Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines.
Sigala S; Faraoni I; Botticini D; Paez-Pereda M; Missale C; Bonmassar E; Spano P
Clin Cancer Res; 1999 May; 5(5):1211-8. PubMed ID: 10353759
[TBL] [Abstract][Full Text] [Related]
15. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
16. CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability.
Fraser MM; Watson PM; Fraig MM; Kelley JR; Nelson PS; Boylan AM; Cole DJ; Watson DK
Cancer Res; 2005 Jul; 65(14):6228-36. PubMed ID: 16024624
[TBL] [Abstract][Full Text] [Related]
17. Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene.
Burney TL; Rockove S; Eiseman JL; Jacobs SC; Kyprianou N
Prostate; 1994 Oct; 25(4):177-88. PubMed ID: 8084835
[TBL] [Abstract][Full Text] [Related]
18. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
19. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.
Fujinami K; Uemura H; Ishiguro H; Kubota Y
Int J Mol Med; 2002 Aug; 10(2):173-6. PubMed ID: 12119554
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
